Brief: Dogwood Therapeutics Reports Positive Interim Phase 2B Results In Chemotherapy-Induced Neuropathic Pain
22/12/2025 17:16
Dec 22 (Reuters) - Dogwood Therapeutics Inc DWTX.O: DOGWOOD THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2B CLINICAL TRIAL RESULTS IN CHEMOTHERAPY INDUCED NEUROPATHIC PAIN DOGWOOD THERAPEUTICS INC - EXPECTS TOP-LINE RESULTS IN Q3 2026 Source text: ID:nGNX2BBZXP Further company coverage: DWTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study